Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP51A1 | Q16850 | 6/20 | 0.44 |
| ▸ | ADRB3 | P13945 | 7/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | PTAFR | P25105 | 1/20 | 0.35 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4478310 | 0.92 | ADRB3 (0.46) | CYP51A1ADRB3ADRB1ADRB2 | |
| SCHEMBL4474151 | 0.89 | ADRB3 (0.51) | ADRB3ADRB1ADRB2 | |
| SCHEMBL4478428 | 0.85 | ADRB3 (0.54) | ADRB3ADRB1ADRB2 | |
| SCHEMBL4463094 | 0.84 | ADRB3 (0.47) | CYP51A1ADRB3ADRB1CYP11B1CYP11B2 | |
| SCHEMBL4479978 | 0.83 | ADRB3 (0.45) | CYP51A1ADRB3ADRB1SLC2A1ADRB2 | |
| SCHEMBL4456601 | 0.83 | CYP4A11 (0.37) | ADRB3ADRB1 | |
| SCHEMBL26177749 | 0.83 | CYP51A1 (0.63) | CYP51A1ADRB3 | |
| SCHEMBL30605113 | 0.83 | CYP51A1 (0.63) | CYP51A1ADRB3 | |
| SCHEMBL4479779 | 0.82 | ADRB3 (0.53) | ADRB3ADRB1ADRB2 | |
| SCHEMBL4468519 | 0.81 | ADRB3 (0.52) | ADRB3ADRB1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629366-B2 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-08 | — | — | US | disclosed |
| US-20060100252-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-7037938-B2 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2006-05-02 | — | — | US | disclosed |
| US-20040006143-A1 | For therapy of urinary incontinence | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100252-A1 | Aminoalcohol derivatives | H1-0, CHRM2, CHRM1 | CYP51A1 1727/4885ADRB3 130/4885ADRB1 39/4885 |
| US-20040006143-A1 | For therapy of urinary incontinence | H1-0, HRH2, H1-2 | CYP51A1 1390/4885ADRB3 568/4885ADRB1 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.